Invest in Ventoux Biosciences: Transforming the $4B Dupuytren's Disease Market with Novel Treatment

1

Dupuytren's impacts >40m patients in US and Europe and global disease market size est. at USD $4.3B

2

No cure and no approved pharmacologic disease modifying options, surgery is mainstay of treatment

3

High patient dissatisfaction with limited treatment options, strong interest in novel options

4

VEN-201 selected as lead candidate for Dupuytren's, based on pre-clinical evidence and profile

5

World class ensemble of immune-fibrosis experts representing the patient from bench to bedside

6

Awarded Biopharmaceutical Company of the Year (2023 & 2024) by Corporate LiveWire

7

Comprehensive IP strategy; composition of matter (upcoming) and method of use (filed)

Invest in Ventoux Biosciences